ArticleCell biochemistry and biophysics2026
Theranekron D6 Shows Selective Effects on HEL299, A549, and Hep3B cells, Indicating Potential in the Fight Against Cancer.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
backgroundThe study demonstrated that 89.72 µg/mL Theranekron D6 (TD6), 62.46 µM Tanshinone IIA (Tansh), and both Tansh-TD6 (Mix) exhibited selective apoptotic mechanisms on HEL299, A549, and Hep3B cells. MATERIALS AND
methodsApplication doses were determined by MTT assays. Apoptotic and ROS-affected cells were assessed via flow cytometry, gene expression changes by qRT-PCR, and mitochondrial membrane potential alterations through fluorescence microscopy.
resultsTansh reduced cell viability in all three cell lines, whereas the application of Mix increased cell viability in HEL299 cells, had no effect on A549 cells, and significantly decreased viability in Hep3B cells. This situation has also shown similarities in studies on ROS, mitochondrial membrane potential, and apoptosis. qRT-PCR analysis showed that in HEL299, Tansh, TD6, and Mix upregulated XIAP (2.42-fold, 1.4-fold, and 1.72-fold) and c-IAP1(2.97-fold, 1.44-fold, and 1.67-fold), whereas SMAC induction by Tansh was attenuated in the Mix (2.49-fold to 1.45-fold). In A549, Tansh strongly upregulated XIAP (3.86-fold), c-IAP1 (5.14-fold), and SMAC (5.02-fold), while TD6 downregulated them (0.4-fold, 0.68-fold, and 0.58-fold). In Hep3B, XIAP (0.63-fold, 0.61-fold, and 0.29-fold) and c-IAP1 (0.3-fold, 0.36-fold, and 0.08-fold) were consistently downregulated with all appplication, while SMAC expression was markedly elevated with Tansh (5.23-fold), TD6 (3.46-fold), and Mix (8.59-fold) applications. Apoptosis increased in HEL299 with Tansh (59.62%) but decreased with Mix (17.56%), whereas in Hep3B it rose with Mix (50.76% to 59.75%).
conclusionTD6 enhances or sustains anticancer activity in malignant cells, suggesting therapeutic potential in combination strategies for many types of cancers.
Indexed as
Identifiers
41105311What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.